Drug Profile
Runcaciguat modified release - Bayer
Alternative Names: BAY 1101042; sGC Activator 1Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bayer
- Class Amines; Chlorobenzenes; Cyclopropanes; Fluorinated hydrocarbons; Propionic acids; Small molecules; Urologics
- Mechanism of Action Guanylate cyclase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diabetic retinopathy; Renal failure
Most Recent Events
- 29 Apr 2022 Bayer completes the CONCORD phase II trial in Renal failure in Germany, Israel, Slovakia, Ukraine, Sweden, Poland, Italy, Finland, Bulgaria, Spain, Belgium, Austria, Denmark (PO) (NCT04507061)
- 13 Jul 2021 Bayer prematurely terminates its phase I trial in Renal failure (In Volunteers) in Germany (PO, Tablet) due to changes in the company's development strategy(NCT04820621) (EudraCT2020-005716-22)
- 07 Apr 2021 Bayer initiates a phase I trial in Renal failure (In Volunteers) in Germany (PO, Tablet) (NCT04820621) (EudraCT2020-005716-22)